Investors Rushing To Take Advantage Of Global Cannabis Boom

Visionary Executive Behind Early Marijuana Success Stories Appears Poised to Do It Again with Scythian Biosciences Corp. (TSX.V: SCYB); (OTC: SCCYF)

One of the highest-upside investment opportunities available right now is in the booming legal marijuana market.

Experts are projecting that global spending on legal cannabis is projected to grow from its current level of just under $10 billion to a whopping $57 billion in the next ten years – a compound annual growth rate (CAGR) of roughly 20% per year.

“The world has never seen something that will have such consistent growth over such a long period of time as the cannabis industry,” said Troy Dayton, CEO of Arcview Market Research, a leading research firm.

Thanks to the growing legalization trend, a number of forward-thinking companies are now moving quickly to establish positions in newly-opened markets.

One such company is Scythian Biosciences Corp. (TSX.V SCYB); (OTC: SCCYF) – a trend-setting company that is making strides in research and development as well as licensing, cultivation and distribution.

Legalization Trend Sends Shares of Many Pot Stocks Soaring

Investors looking to play this once-in-a-lifetime legalization trend have seen shares of many marijuana companies soar.

In fact, since its debut in April 2017, the Horizons Marijuana Life Sciences Index ETF – an exchange traded fund that seeks to replicate the returns of the North American Medical Marijuana Index – has shot up 81.37%.

And shares of a number of individual cannabis stocks have soared over the past 12 months:

• Aurora Cannabis (TSE: ACB) – market cap $5.34 billion – has seen its shares rise by 381.82% over the past year…
• Canopy Growth Corp. (TSE: WEED) – market cap $6.69 billion – has shot up 228.9% during that time…
• OrganiGram Holdings Inc. (TSX.V: OGI) – market cap $593.9 million – has risen 115.32% over the past year…
• And Aphria Inc. (TSE: APH) – market cap $2.39 billion – has climbed 141.95% over the past 12 months.

But one company – a firm with an expanding global presence – offers investors what could be a smarter, more wide-ranging approach for tapping into the upside potential of the global cannabis boom.

And it’s a company being guided by some of the same executives that helped build Aphria Inc. (TSX: APH) – one of Canada’s first marijuana companies – into a successful firm with a $2.3 billion market cap.

Scythian Biosciences (TSX.V: SCYB); (OTC: SCCYF) Offers Research & Development PLUS Global Distribution Potential

That company is Scythian Biosciences Corp. (TSX.V: SCYB); (OTC: SCCYF).

Scythian Biosciences Corp. offers investors both a research and development cannabis play as well as exposure to the global marijuana markets as a distributor.

Just recently – in February 2018, Scythian Biosciences Corp. announced the closing of an offering that included an investment of more than $14 million into the company by Aphria Inc. (TSX: APH).

This investment makes Aphria Inc. a major stakeholder in Scythian Biosciences Corp – and Aphria has the opportunity to increase its position.

Aphria Inc., of course, is one of Canada’s leading producers, suppliers and sellers of medical cannabis and has established a reputation as one of the lowest-cost producers in the Canadian cannabis industry.

Visionary Executive is at it Again…

Scythian’s Board of Directors includes George Scorsis. Mr. Scorsis brings over 15 years of leadership experience, having led companies to rapid growth within highly regulated areas such as alcohol, energy drinks and, most recently, medical cannabis.

Mr. Scorsis was formerly with Mettrum Health Corp as President and helped build that company into a $430 million business prior to its acquisition by Canopy Growth Corp.

His Florida business – Liberty Health Sciences (CSE: LHS) – is poised to take advantage of significant near and mid-term growth opportunities in the rapidly-growing Florida market and has established a goal of becoming the lowest cost cannabis producer in the market.

Scythian Biosciences Now Poised to Enter Argentina Cannabis Market

On April 9, 2018 Scythian Biosciences Corp. (TSX.V: SCYB); (OTC: SCCYF) announced that ABP S.A. – the Argentina-based pharmaceutical import and distribution company that Scythian is in the process of acquiring – received its license to import CBD oil into Argentina.

Previously – in March 2018 – Scythian announced that it had entered into a letter of intent to purchase MMJ International Investments Inc., a company pursuing medical cannabis opportunities in South America. MMJ is the owner of ABP S.A.

With the potential acquisition of one of Argentina’s leading importers and distributors of pharmaceuticals – and with ABP S.A.’s receipt of its license to import CBD oil into Argentina – Scythian is taking a bold step into the Argentinian medical cannabis market.

If this deal is completed, it will give the company access to Argentina’s network of hospitals, doctors, retail pharmacies, private health providers and public health system and will advance the Company’s objective to provide patients with access to safe, pharmaceutical-grade medical cannabis.

Scythian Biosciences (TSX.V: SCYB); (OTC: SCCYF)
Has Also Entered the Jamaican Market

Soon after announcing its proposed entry into the Argentinian medical cannabis market, Scythian Biosciences Corp. (TSX.V: SCYB); (OTC: SCCYF) announced the next step in its plan to expand its reach globally.

On March 21, 2018 the company announced that the Jamaica Cannabis Licensing Authority has granted Marigold Jamaica Products Ltd., a company that Scythian is proposing to acquire a 49% stake in, five conditional licenses to research, cultivate, process and market medical cannabis, as well as provide therapeutic or spa services utilizing cannabis products.

The awarding of five licenses is the most ever granted to one company by the Jamaican Cannabis Licensing Authority and these licenses include:

• A Tier 3 conditional license to cultivate over five acres (20,235 square meters) of land with cannabis for medical, scientific and therapeutic purposes. Scythian is the first company to be granted this license for over five acres of cannabis cultivation.
• A Tier 2 conditional license to process cannabis for medical, scientific and therapeutic purposes, including the manufacturing of cannabis-based products, in a space of over 200 square meters.
• A herb house retail license to sell cannabis products for medical, scientific and therapeutic purposes, with a space for immediate consumption by consumers.
• A therapeutic retail license to provide therapeutic or spa services utilizing cannabis products.
• A research license to undertake all activities involved in the assessment, study, research, development and testing of products derived from all or any part of the cannabis plant.

Scythian Biosciences Announces its Intent to Enter the Colombian Cannabis Market

In April 2018, Scythian Biosciences Corp. (TSX.V: SCYB); (OTC: SCCYF) announced it had signed a binding letter of intent to acquire MMJ Colombia Partners Inc. This acquisition will result in 100% ownership of MMJ Colombia for Scythian and would provide entry into the Colombian market for Scythian.

The acquisition is conditional upon the completion of MMJ Colombia’s acquisition of ColCanna SAS and ColCanna’s receipt of the final Colombian licenses for the cultivation, production, research and export of medical cannabis CBD and THC extracts.

ColCanna is the first medical cannabis producer in the Colombian coffee zone to receive pending licenses to cultivate, produce, research, and export medical cannabis CBD and THC extracts.

It is a government-backed operation with 35 acres of available land in Chinchina, Caldas, Colombia, all of which is expected to be developed and used for the cultivation of cannabis. Located in a temperate climate that supports four harvests a year, the first of which is expected in late 2018, this area is ideal for year-round cultivation without the need for artificial climate control.

Currently, ColCanna is in the process of constructing over 500,000 square feet of total greenhouse production space and is planning to build its laboratory for the fabrication of cannabis extracts in a warehouse located in Pereira. Following construction, ColCanna anticipates that these facilities will be capable of producing over 2,600,000 ml of medicinal oil per year.

With its entry into Argentina, Jamaica and Colombia, Scythian Biosciences Corp. (TSX.V: SCYB); (OTC: SCCYF) has signaled its intent to become a significant player in the global cannabis distribution industry.

This entry into the global distribution market provides an outstanding complement to the company’s existing cannabinoid-based drug development program.

Scythian Biosciences Corp. Looks to Treat Traumatic Brain Injury with Cannabinoids

Scythian Biosciences Corp. (TSX.V: SCYB); (OTC: SCCYF) is in the process of developing a proprietary cannabinoid-based combination drug therapy for the treatment of concussions and traumatic brain injury.

In fact, Scythian’s first patent application covers a two-drug combination therapy for concussive treatment.

This therapy involves the combined use of an NMDA antagonist plus a CB2 agonist, either cannabinoid or non-cannabinoid. NMDA antagonists inhibit white blood cell activity within injured brain tissue, stopping cytokine release and further brain damage. CB2 agonists modulate the inflammatory response itself, easing the initial swelling and the resulting pressure of injured brain tissue against the skull.

Simply put, the company believes that through its unique technology, brain damage caused by concussions can be greatly mitigated by easing the aftereffects of the brain’s contact with the skull.

Most of the damage occurs during the inflammatory and immune responses which are triggered immediately following a brain injury.

It is precisely these processes that Scythian’s patent-pending technology aims to control, thereby helping the body repair brain tissue without the associated swelling and white blood cell infiltration.

Scythian’s second patent filing covers methods and compositions for treating gastrointestinal inflammation. This includes the use of the cannabinoid CBD, the same CB-2 agonist covered in our concussion treatment combination, together with an NMDA receptor or FAAH inhibitor to control intestinal inflammation.

Scythian Has Partnered with the University of Miami to Conduct Clinical Trials

Scythian has recently formed a collaboration with the University of Miami and its world-renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen.

The University of Miami believes that Scythian’s scientific approach shows significant promise and differs from previous approaches to treat this growing problem.

The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian’s clinical studies to be undertaken at their world-class facilities.

Nationally recognized behavioral neuroscientist Gillian Hotz is leading the University of Miami study. An expert in neurotrauma, concussion management and neurorehabilitation, Hotz has been the co-director of the Miller School’s Concussion Program since 1995.

In addition to the University of Miami partnership, Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.

Why Investors Should Consider Adding Shares of Scythian Biosciences Corp. (TSX.V: SCYB); (OTC: SCCYF)

Investors looking to take advantage of the booming global market for legal marijuana have already seen significant growth over the past 12 to 18 months.

The months ahead are projected for even stronger growth in the overall market as legalization becomes more widespread.

Scythian Biosciences Corp. (TSX.V: SCYB); (OTC: SCCYF) is positioning itself to take advantage of this global growth by pursuing opportunities in new markets, such as Argentina, Jamaica and Colombia to date.

This move to become a leading global distributor of medical marijuana is perfectly complemented by the company’s research and development efforts, as Scythian – in partnership with the University of Miami – pushes ahead with clinical trials of its cannabinoid-based combination drug therapy for the treatment of concussions and traumatic brain injury.

And just recently – on February 22, 2018 – Scythian Biosciences rang the closing bell at the Nasdaq Stock Market to mark the company’s admission into the Nasdaq International Designation program under the symbol “OTC – Nasdaq Intl: SCCYF”.

This Nasdaq International Designation will help increase the visibility of Scythian to the U.S. investment community and U.S. market makers.

Investors looking for smart exposure to the global legal marijuana industry should begin their due diligence right away and consider adding shares of Scythian Biosciences Corp. (TSX.V: SCYB); (OTC: SCCYF) to their portfolio.

Please read our disclaimer notice here: Disclaimer Notice